Raymond James Financial
DMAC icon

Raymond James Financial’s DiaMedica Therapeutics DMAC Stock Holding History

Raymond James Financial’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111K Hold
15,791
– – ﹤0.01% 5160
2026
Q1 		$107K Sell
15,791
-10
-0.1% -$79 ﹤0.01% 5020
2025
Q4 		$126K Sell
15,801
-20,700
-57% -$155K ﹤0.01% 4888
2025
Q3 		$251K Buy
36,501
+20,734
+132% +$112K ﹤0.01% 4510
2025
Q2 		$61.5K Buy
15,767
+100
+0.6% +$390 ﹤0.01% 5100
2025
Q1 		$59.4K Buy
15,667
+400
+3% +$2.29K ﹤0.01% 4623
2024
Q4 		$82.9K Buy
+15,267
New +$72K ﹤0.01% 4552

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Raymond James Financial's DMAC Position: Q2 2026 in Review

Raymond James Financial held its DiaMedica Therapeutics (DMAC) position steady in Q2 2026 at 15,791 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #5160.

Raymond James Financial first reported a position in DMAC in Q4 2024 and has held it in 7 quarters since. The position peaked at $251K in Q3 2025. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Raymond James Financial held 15,791 shares of DiaMedica Therapeutics worth $111K as of Q2 2026.
  • Raymond James Financial left its DiaMedica Therapeutics share count unchanged in Q2 2026.
  • DiaMedica Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5160 holding.
  • Raymond James Financial first reported a position in DiaMedica Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's DiaMedica Therapeutics position peaked at $251K in Q3 2025.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.